6/11
12:34 am
fsnuy
Business Transformation: 4 Industry-Leading Companies Doing It Right [Forbes]
Medium
Report
Business Transformation: 4 Industry-Leading Companies Doing It Right [Forbes]
5/13
09:57 am
fsnuy
Compounding Pharmacy Global Strategic Business Report 2024: Market to Reach $17.7 Billion by 2030 from $13 Billion in 2023 [Yahoo! Finance]
Low
Report
Compounding Pharmacy Global Strategic Business Report 2024: Market to Reach $17.7 Billion by 2030 from $13 Billion in 2023 [Yahoo! Finance]
5/8
04:39 am
fsnuy
STRABAG and PORR to acquire parts of VAMED group for €90m [Yahoo! Finance]
Low
Report
STRABAG and PORR to acquire parts of VAMED group for €90m [Yahoo! Finance]
5/7
04:12 pm
fsnuy
Fresenius Boosts Forecast, Confirms Plans to Exit Vamed Business [BNN Bloomberg (Canada)]
Low
Report
Fresenius Boosts Forecast, Confirms Plans to Exit Vamed Business [BNN Bloomberg (Canada)]
5/7
10:36 am
fsnuy
Fresenius Said to Plan Elimination of Vamed in Streamlining Step [BNN Bloomberg (Canada)]
Medium
Report
Fresenius Said to Plan Elimination of Vamed in Streamlining Step [BNN Bloomberg (Canada)]
5/2
02:20 pm
fsnuy
Fresenius Sells Controlling Stake in Vamed Rehab Business to PAI [BNN Bloomberg (Canada)]
Neutral
Report
Fresenius Sells Controlling Stake in Vamed Rehab Business to PAI [BNN Bloomberg (Canada)]
4/30
01:40 am
fsnuy
Institutions own 30% of Fresenius SE & Co. KGaA (ETR:FRE) shares but retail investors control 43% of the company [Yahoo! Finance]
Low
Report
Institutions own 30% of Fresenius SE & Co. KGaA (ETR:FRE) shares but retail investors control 43% of the company [Yahoo! Finance]
4/15
12:27 pm
fsnuy
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
Low
Report
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.